Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved 25 thousand 800 participants across 21 sites.
The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group versus 7 cases observed in the Covaxin group resulting in vaccine efficacy of 81 per cent.
The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research.
Director-General of Indian Council of Medical Research, Dr. Balram Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months’ time showcases the immense strength of Atmanirbhar Bharat. He said, it is also a testament to India’s emergence as a global vaccine superpower.
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogenicity against the rapidly emerging variants.